NCT01002040 - Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

July 31, 2010

Study Completion Date

August 31, 2010

Conditions

HIV InfectionsH1N1 Influenza

Interventions

BIOLOGICAL

Arepanrix

Group A receives one dose of Arepanrix

BIOLOGICAL

Arepanrix

Group B receives 2 doses of Arepanrix 3 weeks apart

Trial Locations (4)

Dalhousie University, Halifax

University of Ottawa / Ottawa Hospital Research Institute, Ottawa

University of Toronto, Toronto

McGill University, Montreal